Kehitetty ADAM17-inhibiittori ZLDI-8, joka inhiboi Notchsignaloinnin HCC soluissa(2018)

http://www.probechem.com/products_ZLDI-8.aspx
Tämä ei ole   kliininen lääke.
 Zhang Y et al. 2018:

ZLDI-8 (ZLDI8;IAC-8)

Catalog No.: PC-35373Not For Human Use, Lab Use Only.

ZLDI-8 (IAC-8) is a novel Notch signaling pathway inhibitor for Notch activating/cleaving enzyme ADAM-17, significantly decreases the level of NICD and accumulation of NICD in the nucleus.

 ZLDI-8 (IAC-8) is a novel Notch signaling pathway inhibitor for Notch activating/cleaving enzyme ADAM-17, significantly decreases the level of NICD and accumulation of NICD in the nucleus; exhibits cytotoxic activity against MHCC97-H cells with IC50 of 5.32 uM, reduces the expression of pro-survival/anti-apoptosis regulators, Survivin and cIAP1/2, also increases the expression of epithelial marker E-Cadherin and reduces mesenchymal markers N-Cadherin and Vimentin in HCC cells; significantly disrupted the activity of Notch pathway in HCC cells and inhibits the epithelial-mesenchymal transition (EMT) process of HCC cells; ZLDI-8 treatment enhances the susceptibility of HCC cells to Sorafenib, Etoposide, and Paclitaxel both in vitro and in vivo.

 Related  products. Target Notch
http://www.probechem.com/target_Notch.aspx

Tässä lähteessä mainitaan muita Notch- inhibiittoreita, mutta niistä mikään ei ole varsinaisia ADAM17-inhibiittoreita.

Muistiin  14.3. 2019